

This PDF is a selection from a published volume from the National Bureau of Economic Research

Volume Title: Economic Dimensions of Personalized and Precision Medicine

Volume Authors/Editors: Ernst R. Berndt, Dana P. Goldman, and John W. Rowe, editor

Volume Publisher: University of Chicago Press

Volume ISBNs: 978-0-226-61106-8 (cloth); 978-0-226-61123-5 (electronic)

Volume URL: <http://www.nber.org/books/bern-13>

Conference Date: September 13–14, 2017

Publication Date: April 2019

Chapter Title: List of contributors, indexes

Chapter Author(s):

Chapter URL: <http://www.nber.org/chapters/c14532>

Chapter pages in book: (p. 335 – 349)

Contributors

Ernst R. Berndt
MIT Sloan School of Management
100 Main Street, E62-527
Cambridge, MA 02142

Amitabh Chandra
John F. Kennedy School of
Government
Harvard University
79 John F. Kennedy Street
Cambridge, MA 02138

Joseph Tung-Chieh Chang
Department of Radiation Oncology
Chang Gung Memorial Hospital and
School of Medicine
Chang Gung University
259 Wen-Hwa 1st Road, Kwei-Shan
District
Taoyuan, Taiwan, R.O.C. 33333

Guy David
The Wharton School
University of Pennsylvania
305 Colonial Penn Center
3641 Locust Walk
Philadelphia, PA 19104-6218

Karen Eggleston
Shorenstein Asia Pacific Research
Center
Stanford University
Encina Hall E301
Stanford, CA 94305-6055

Shawn Garbett
Department of Biostatistics
Vanderbilt University School of
Medicine
2525 West End Avenue
Nashville, TN 37203

Craig Garthwaite
Department of Strategy
Kellogg School of Management
Northwestern University
2001 Sheridan Road
Evanston, IL 60208

Dana P. Goldman
Schaeffer Center for Health Policy and
Economics
Sol Price School of Public Policy and
USC School of Pharmacy
University of Southern California
635 Downey Way
Los Angeles, CA 90089-3333

Philippe Gorry
University of Bordeaux
Health Sciences College, Medical
School and Research Unit in
Theoretical & Applied Economics—
UMR CNRS 5113
Department of Social & Human
Sciences
University of Bordeaux
Avenue Leon Duguit
33608 Pessac, France

Jove Graham
Geisinger Health Systems
Center for Health Research
100 North Academy Avenue
Danville, PA 17822

John A. Graves
Vanderbilt University School of
Medicine
2525 West End Avenue, Suite 1200
Nashville, TN 37203

Manuel Hermosilla
Carey Business School
Johns Hopkins University
100 International Drive
Baltimore, MD 21202

Jason Hockenberry
Department of Health Policy and
Management
Rollins School of Public Health
Emory University
1518 Clifton Road
Atlanta, GA 30322

David H. Howard
Department of Health Policy and
Management
Emory University
1518 Clifton Road NE
Atlanta, GA 30322

Kristopher J. Hult
Charles River Associates
1 South Wacker Drive #3400
Chicago, IL 60606

Jorge Lemus
Department of Economics
University of Illinois, Urbana-
Champaign
1407 W. Gregory Drive
Urbana, IL 61874

Frank R. Lichtenberg
Graduate School of Business
Columbia University
504 Uris Hall
3022 Broadway
New York, NY 10027

Jui-fen Rachel Lu
Graduate Institute of Business and
Management and Department of
Health Care Management
Chang Gung University
259 Wen-Hua 1st Road, Kwei-shan
District
Taoyuan, Taiwan, R.O.C. 33302

Daniel Maeng
Department of Epidemiology and
Health Services Research
Geisinger Health Systems
100 North Academy Avenue
Danville, PA 17822

Mark V. Pauly
Health Care Management Department
The Wharton School
University of Pennsylvania
208 Colonial Penn Center
3641 Locust Walk
Philadelphia, PA 19104-6218

Josh F. Peterson
Department of Biomedical Informatics
Vanderbilt University Medical Center
2525 West End Avenue
Nashville, TN 37203

Tomas J. Philipson
Council of Economic Advisers
The White House
1600 Pennsylvania Avenue, NW
Washington, DC 20500

Rebecca A. Pulk
Geisinger Precision Health Center
190 Welles Street, Suite 128
Forty Fort, PA 18704

John W. Rowe
School of Public Health
Columbia University
600 West 168th Street, 6th Floor
New York, NY 10032

Ariel Dora Stern
Harvard Business School
Morgan Hall 433
Boston, MA 02163

Mark R. Trusheim
MIT Sloan School of Management
100 Main Street, E62-518
Cambridge, MA 02142

Diego Useche
CRÉM-CNRS
Faculté des Sciences Économiques
University of Rennes 1
7, Place Hoche CS 86514
35 065 Rennes Cedex, France

Marc S. Williams
Department of Epidemiology and
Health Services Research
Geisinger Health Systems
100 North Academy Avenue
Danville, PA 17822

Eric Wright
Department of Epidemiology and
Health Services Research
Geisinger Health Systems
100 North Academy Avenue
Danville, PA 17822

Zilu Zhou
Department of Health Policy
Vanderbilt University Medical Center
2525 West End Ave, Suite 1200
Nashville, TN 37203

Author Index

- Abdul-Husn, N. S., 276
Acemoglu, D., 126n25
Adams, J. D., 24
Ahmadpoor, M., 24
Ainsworth, R., 89
Alarid-Escudero, F., 70
Alexander, B. M., 120, 122
Andersen, J. N., 186n6
Anderson, G. F., 331
Anderson, T. W., 322
Appold, K., 241
Asano, H., 241
Asbury, C. H., 308
Aspinall, M. G., 1, 159
Avorn, J., 311
Azoulay, P. J., 24, 48
- Bae, Y. H., 93
Baker, L. C., 223
Baltagi, B. H., 322
Barabási, A.-L., 23
Barro, J. R., 223
Basu, A., 60, 61, 185n1, 186, 190n12, 194, 200n29
Bates, P. A., 31
Bauer-Mehren, A., 22, 23, 31
Begg, E. J., 101
Bekelman, J., 223
Berger, J. R., 190
Berm, E. J., 54
Bermeman, D., 18
- Berndt, E. R., 2, 16, 87, 88, 89, 105, 106, 126, 126n25
Bespalov, A., 128
Birner, P., 89
Blavin, F. E., 161
Blundell, R., 34, 48
Bontardelli, F., 274
Borse, M. S., 274
Boyle, E. A., 22, 22n3
Braslow, J., 185n1
Brau, J., 311, 316, 317, 319, 322
Brekke, K. R., 110
Brewer, M., 24
Brune, K., 48n23
Budish, E., 121, 123, 123n18
- Campbell, J. D., 70
Cao, C., 25n5
Carey, D. J., 56, 275
Carlson, B., 96
Caro, J. J., 62
Carreyrou, J., 223
Carter, R., 317
Cavalari, L., 273
Chan, C., 246n4
Chandra, A., 117, 120, 122, 124
Chang, C.-M., 239
Chang, J. T.-C., 266, 267
Chang, S. J., 314
Chemmanur, T., 314
Cheng, S. H., 240, 269

- Chiang, C.-J., 248
Chin, L., 186n6
Chok, J., 317
Claxton, K., 60
Cockburn, I., 24, 48
Cohen, J. P., 58
Cohen, J. T., 70, 74
Cohen, W. M., 24
Collier, R., 210
Collins, F. S., 54
Comans, T., 62
Conn, J., 54
Conti, A., 329
Conti, R. M., 126n25
Costa, D. B., 1
Costinot, A., 138
Côté, A., 329, 331
- Daiger, S. P., 22
Daly, B., 246n4
Danese, M. D., 269n6
Danzon, P. M., 105, 306, 308
Darby, M., 24
David, G., 230
Davis, J. C., 2
De Angelis, C., 127, 127n26
Delaney, J. T., 58
Deneer, V. H., 275
Denny, J. C., 54, 58
Denoncourt, R. N., 105
Derfuss, T., 198, 210
DeSantis, C. D., 243
DeSimone, J., 11
Devonshire, V., 212
Dewey, F. E., 275, 276
Dinan, M. A., 219
Dionne, C. A., 212
Dong, M., 330
Dorsch, M. P., 297, 299
Douglas, F. L., 2, 16, 87, 88
Dowd, B. E., 253
Dranove, D., 24, 38n19
Duan, L. N., 185n1
DuBois, P., 126n25
Dzau, V. J., 2
- Egan, M., 10, 11, 12, 187
Eggleston, K., 266, 267
Einav, L., 244, 247
Espinoza, M. A., 194
Evans, J. P., 24
- Faber, J., 307, 310
Fan, L., 239
Faulkner, E., 58
Fawcett, S., 311, 316, 317, 319, 322
Feero, W. G., 53, 54, 58
Ferlay, J., 244
Filpova-Neumann, L., 161
Finkelstein, A., 244, 247
Fleming, L., 23
Fragoulakis, V., 53, 54
Freedman, M. S., 190
Fridlyand, J., 121
Frueh, F. W., 54, 58
Fudenberg, D., 106
Fulghieri, P., 314
Furie, B., 72
Futreal, P. A., 186n6
- Gage, B. F., 63, 75
Gajofatto, A., 201, 201n30, 202, 204n35
Gambardella, A., 24
Garden, H., 308, 328
Gardiner, S. J., 101
Garrison, L. P., 63
Garrison, L. P., Jr., 269n6
Garthwaite, C., 38n19, 117, 124
Gaughan, E. M., 1
Gaynor, M., 163
Ghate, S. R., 57
Gianni, L., 239
Ginsburg, G., 54
Glick, H. A., 180
Goh, K.-I., 23, 29
Goldhaber-Fiebert, J. D., 70
Goldman, D. P., 2, 48n23, 186
Gompers, P. A., 306, 316, 322
Gorry, P., 308, 328
Goss, P. E., 239
Gottesman, O., 54, 56, 60
Graf, M. D., 164
Graves, J. A., 55
Green, R. C., 56
Griffith, R., 34, 48
Grosse, S., 58
Grossman, G. M., 110
Grutters, J. P. C., 194
Gulati, R., 314
Gulbahce, N., 23
Guo, R.-J., 306, 313, 331
Gupta, R., 209
Gusarova, V., 276

- Haas-Wilson, D., 163
 Haggerty, C. M., 275
 Hall, B. H., 48
 Hall, S. N., 62
 Halpern, R., 212
 Hamermesh, R. G., 1, 159
 Hay, J. W., 63
 Hay, M., 307, 315
 Hayden, E., 22
 Heeley, M. B., 306, 309
 Helwick, C., 88
 Henderson, R., 24, 48
 Henkel, J., 309
 Hermosilla, M., 38n19
 Hicks, I., 242
 Higgins, M. C., 314
 Higgins, M. J., 307, 313, 314, 317, 319, 324, 329
 Higuera, V., 198n26
 Hillman, A. L., 165
 Hirschleifer, D., 330
 Ho, C., 166
 Ho, M. L., 244
 Hoang, H., 306, 314
 Hoenen, S., 309
 Hoenig, D., 309
 Holland, K., 207n44
 Hollenbeck, B. K., 223
 Hollingsworth, J. M., 223
 Hoy, M., 161
 Hsiao, C., 322
 Hsing, M., 58
 Hsu, D., 306, 309
 Hu, S. X., 87, 89
 Huckfeldt, P., 10
 Huckman, R. S., 223
 Hudis, C. A., 1
 Hughes, D. A., 330
 Hughes, J. P., 315
 Hult, K. J., 187, 188, 192, 194
 Humer, C., 106
 Hunter, D. J., 218
 Hutchinson, R. A., 185n4
 Hybels, R. G., 306, 314
 Hyn, J.-W., 209

 Iizuka, T., 223

 Jacobson, S. H., 62
 Jaffe, A. B., 24, 187
 Jain, N., 306, 309

 Jalal, H., 70
 Jang, J. S., 274
 Jena, A. B., 200n29
 Jiang, M., 275
 Johnson, J. A., 60
 Johnson, S. G., 275
 Jonsson, P. F., 31

 Kakwani, N., 251
 Kalia, S. S., 56
 Kanavos, P., 138
 Karnon, J., 62
 Kazi, D. S., 54, 72
 Kerem, B.-S., 25
 Kesselheim, A. S., 311
 Kessler, D. P., 223
 Khalili, H., 297
 Khant-Akom, S., 322
 Khoury, M. J., 53, 58, 60
 Klein, T. E., 56
 Koboldt, D. C., 25
 Kohane, I. S., 58
 Kong, S. W., 58
 Kotz, S., 186n3, 195, 195n21
 Kravitz, R. L., 185n1
 Krein, S. L., 223
 Kuhn, M., 110
 Kuntz, K. M., 70

 Lander, E. S., 22
 Layne, T., 238
 Lazonick, W., 307, 308
 Leland, H. E., 317, 319
 Lerner, J., 306
 Lev, B., 306, 313, 331
 Levine, G. N., 274
 Lewis, C. M., 72
 Li, J., 246
 Li, Y. I., 22, 22n3
 Lien, H. M., 249
 Lin, M. H., 244, 251
 Lin, S. J., 244, 246n4
 Lindsley, C. W., 329
 Linn, J., 126n25
 Liu, L., 242
 Loibl, S., 239
 Londin, E., 25
 Long, C., 306, 309
 Loscalzo, J., 23
 Loughran, T., 306, 317, 319
 Lu, J.-f. R., 266, 267

- Lucchinetti, C., 198
Luzum, J., 273
- MacArthur, J., 25
Machlin, S. R., 54
MacLean, H. J., 190
Mairesse, J., 48
Malucchi, S., 191
Manaster, S., 317
Mann, R., 306, 309
Manolio, T. A., 22
Mansfield, E., 24, 306
Mathias, P. C., 273
Matusik, S. F., 306, 309
McCarthy, M. I., 25
McGuire, T. G., 105, 219
Megginson, W. L., 316, 319, 322
Meltzer, D., 60, 194
Merlini, P. A., 274
Mishra, P., 55
Mitchell, J. M., 223
Mohnen, P., 48
Möller, J., 62
Momary, K. M., 297, 299
Moors, E. H. M., 307, 310
Moult, J., 25n5
Mukesh, B., 222
Mullard, A., 315, 316
Mullins, C. D., 93
Murphy, S. J., 126n25
Murray, M. F., 275
Myers, J. A., 311
- Nabel, E. G., 53, 54
Nadarajah, S., 186n3, 195, 195n21
Nall, R., 207
Nallamotheu, B. K., 223
Nelson, P., 2, 190n13
Nelson, R. R., 24
Neuman, M., 60, 230
Neumann, P. J., 66, 70, 72, 74, 241
Newhouse, J. P., 105
Nicholson, S., 306, 308
Nikpay, S. S., 55
Norton, E. C., 253
Notarangelo, M. F., 274
- Oi, W. Y., 17
Olopade, O. I., 246n4
Olson, M. K., 322
- Pacanowski, M., 54
Palmer, B., 22
- Pan, H.-B., 244
Paris, V., 308, 328
Parkins, D. M., 244
Paul, S. M., 309, 315
Pauly, M. V., 160, 161, 162, 219, 241
Pavlovic, D., 191
Pereira, N. S., 105, 306, 308
Perez, E. A., 269n6
Peterson, J. F., 54, 55, 60, 77
Peterson, J. L., 63n3
Philipson, T. J., 10, 11, 12, 186, 187, 200n29
Phillips, K. A., 54
Pietrangelo, A., 198n26
Pignol, J.-P., 222
Pindyck, R. S., 89, 104, 111
Piñero, J., 29
Pisani, P., 244
Pisano, G. P., 306, 307, 308
Pistoresi, R. H., 212
Podolny, J. M., 305, 307, 309
Poletti-Hughes, J., 330
Pollack, A., 24, 48n23, 95, 105
Pritchard, J. K., 22, 22n3
Prosser, L. A., 212
Pulley, J. M., 54, 58
Pyle, D. H., 317, 319
- Qian, J., 317
- Relling, M. V., 56
Reynolds, M. W., 212
Río, J. M., 187, 201, 209
Risch, N., 22á3
Ritter, J., 306, 317, 319
Ritter, J. R., 311, 314, 319
Roberts, K. B., 222, 223
Rohde, D. D., 308
Roin, B. N., 121, 123, 123n18
Romond, E. H., 269n6
Rosenberg, N., 24
Ross, D., 103
Rubinfeld, D. L., 89, 104, 111
Ruff, C. T., 48n23
Rush, C. A., 190
Rzakhanov, Z., 307, 308, 310, 311
- Sabouret, P., 273
Schildcrout, J. S., 57, 59, 273
Schwartz, M., 306
Scott, A. A., 54, 126n25
Scott, S. A., 58, 274, 275, 296
Scott Morton, F. M., 126, 126n25, 307

- Scuffham, P., 62
 Sculpher, M. J., 60
 Segal, J. B., 185
 Seoane-Vasquez, E., 308, 310, 311, 329
 Shapiro, C., 110
 Shreibati, J. B., 223
 Shurin, S. B., 53, 54
 Siller-Matula, J. M., 297
 Silva, A., 238
 Slamon, D., 269n6
 Smith, B. D., 222, 223
 Snyder, S. R., 273
 Sohn, J.-y., 242
 Sood, N., 10
 Sørensen, P. S., 188
 Sorenson, O., 23
 Spence, M., 305, 309
 Stahl, J. E., 62
 Standfield, L., 62
 Staton, T., 94
 Stephan, P. E., 24, 307, 313, 314, 317, 319, 324, 329
 Stern, A. D., 120, 122, 126, 126n25, 305
 Stern, S., 126, 126n25
 Strasser-Weippl, K., 239
 Stuart, T., 306, 314
 Sunshine, J. H., 223
 Sveikauskas, L., 24
 Swen, J. J., 274
 Swisher, J. R., 62

 Taniel-Sartral, M., 273
 Tamman, M., 223
 Tarazi, W., 238
 Tejwani, S. S., 105
 Teng, K., 58
 Teoh, S. H., 330
 Teutsch, S. M., 60
 Thursby, J. G., 307, 313, 314, 317, 319, 324, 329
 Thursby, M. C., 329
 Tirole, J., 106, 111
 Toole, A. A., 24, 24n4
 Treadaway, K., 212
 Trusheim, M. R., 2, 16, 87, 88, 89, 106, 126
 Tsuchida, J., 244
 Tulum, O., 307, 308

 Useche, D., 306, 309, 315

 Välimäki, J., 18
 Van Bebber, S. L., 54
 Van Doorslaer, E., 251

 Van Schependom, J., 206n38
 Varadhan, R., 185
 Varmus, H., 54
 Vassy, J. L., 58
 Veenstra, D. L., 53, 54, 58
 Verbelen, M., 72
 Verhoef, T. I., 54, 72
 Visscher, P. M., 24, 25n5
 Vogt, W. B., 163

 Wachi, S., 31
 Wagner, S., 306
 Wagstaff, A., 251
 Walsh, J. P., 24
 Wang, C. J., 240, 269
 Wang, Q., 238–39
 Ward, M. R., 24
 Warner, A. C., 105
 Weale, M. E., 72
 Weinstein, M. C., 72, 74
 Weiss, C., 185
 Weiss, K. A., 316, 319, 322
 Weitzel, K. W., 56, 60
 Welch, I., 311, 314, 319
 Wen, T. H., 251
 West, H. J., 126
 Wicklund, C., 53, 54, 58
 Wilbon, A. D., 306
 Williams, H., 121, 123, 123n18, 244, 247
 Windmeijer, F., 34, 48, 322
 Woodcock, J., 54
 Wu, J.-Y., 240, 269
 Wu, R., 31

 Yang, A. C., 251
 Ye, Z., 223
 Yeauw, J., 12f
 Yin, W., 308, 310
 Yoneda, K., 31
 You, J. H., 275

 Zabalza, M., 274, 298
 Zaheer, F., 190
 Zeckhauser, R., 160
 Zhao, L., 242
 Zheng, G., 25n5
 Zhou, N., 306, 313, 331
 Zhu, B., 284n1, 296
 Zick, C. D., 58
 Ziedonis, R. H., 306, 309
 Zineh, I., 54
 Zucker, L., 24

Subject Index

Note: Page numbers followed by “f” or “t” refer to figures or tables, respectively.

- adherence to treatments, 11
- Aegerion Pharmaceuticals, 306
- American College of Medical Genetics (ACMG), 56
- antiplatelet agents, 273–74
- Asia, coverage of personalized medicine in, 241–42. *See also* National Health Insurance (NHI) program of Taiwan; Taiwan
- assessment. *See* risk assessment

- Bertrand competition, precision medicine, 104–6; defending against, 106
- BEST (Biomarkers, EndpointS, and other Tools) Resource, 120
- biological complexity, HDN diseases and, 29–32
- Biologics License Application (BLA), 311
- biomarkers, 123–26; in clinical trials, 135–38; data, 132; defined, 119; genomic, defined, 120; number of trials employing, by type, 131t; precision medicine and, 119–21; summary statistics for selected, 130t; types of, 120n10, 129–32
- Biomarkers, EndpointS, and other Tools (BEST) Resource, 120
- biotech start-ups, 308
- BLA (Biologics License Application), 311
- breast cancer treatment, Taiwanese study of, 243–54; conceptual framework for study of, 246–48; data description for, 248–51; empirical methods for, 251–53; results of study of, 253–67. *See also* National Health Insurance (NHI) program of Taiwan; Taiwan
- burden of disease, for all cancers, 144, 144t

- care delivery, 1
- Clinical Decision Intelligence System (CDIS), 277
- Clinical Pharmacogenomic Implementation Consortium (CPIC), 56
- clinical trials, 117–18, 122; biomarkers and likely precision medicines in, 135–38
- clopidogrel. *See* cytochrome P450 2C19 (CYP2C19)
- Cortellis, 25–26, 26n6, 127
- cost-effectiveness acceptability curve (CEAC), 74–75
- cost outcomes, theoretical possibilities for, with/without genetic testing, 167–69
- cost sharing, illustrative example of, for rare condition, 175t
- coverage. *See* insurance coverage
- CPIC (Clinical Pharmacogenomic Implementation Consortium), 56
- CPIC drug-gene mapping, 64–65, 66t

- cytochrome P450 2C19 (CYP2C19), 273–76; data sources for study of, 277, 278–79t; discussion of results of study of, 295–301; financial/prescription refill information for study of, 281; genetic information for study of, 282, 283t; implications of, for precision medicine, 300–301; population selection for study of, 280–81; results for study of, 285–95; setting for study of, 276–77; statistical analysis for study of, 282–85
- detailed biomarkers database (DBD), 132–33
- diagnostic cutoff prisoners' dilemma: Part 1, 93–97; Part 2: relaxing iso-payoff restriction, 97–99; Part 3: including the payer, 103–4. *See also* precision medicine prisoners' dilemma
- discrete event simulation (DES) model, 62; baseline, 65
- disease, burden of, for all cancers, 144, 144t
- DisGeNet, 23
- dosing game, 101–2
- drug development pipeline, 121–22; characterizing, for likely precision medicines, 133–38; data composition and summary statistics for study of, 128–32, 129f; data used for study of, 127–28; institutional factors for, and likely precision medicines, 138–54; for National Institutes of Health, 4; for personalized and precision medicine, 4
- drug development process, precision medicine and, 119–23
- economics incentives, 116–18
- errors, treatment, 10
- expected value of partial perfect information (EVPPI), 78, 79t
- externalities, of genetic testing, 3–4
- fluorescence in situ hybridization (FISH) diagnostic test, 6
- follow-on drug markets, 126, 126n25
- game theory: features of precision medicine and, 90–93; for oligopolistic situations and, 89–90; for personalized and precision medicine, 4
- genetic analysis, 1
- genetic tests/testing: advantages of, 159; current examples of, 174–80; current patterns of insurance coverage for, 163–66; externalities of, 3–4; primary finding on multiplexed, 55
- genome-wide association studies (GWAS), 22, 24–25
- genomic biomarker, defined, 120
- genomic information, 72t; cost effectiveness of testing strategies for, 72–74; results of value of, 71–72; simulation approach, 62; theory of value, 60–62
- genotype-guided antiplatelet therapy, 273–74
- GWAS (genome-wide association studies) Catalog, 25
- GWAS (genome-wide association studies) publications: empirical strategy for analyzing, 32–36; results of study of, 36–37
- HDN. *See* human disease network (HDN) diseases
- health impacts: of novel/incremental innovation, 192–93; potential, of personalized medicine, 194–98; of seven events in the history of multiple sclerosis treatments, 203–8
- health outcomes, theoretical possibilities for, with/without genetic testing, 167–69
- HGP. *See* Human Genome Project (HGP)
- human disease network (HDN) diseases, 23; biological complexity and, 29–32
- Human Genome Project (HGP), 3; hopes for, 21–22
- human therapeutics, reasons for slow progress in, 22
- IMRT. *See* intensity-modulated radiation therapy (IMRT)
- indication-based pricing, 117
- individual treatment value, learning about, through experience, 11–16
- initial public offerings (IPOs), orphan drugs and, 315–16
- insurance coverage: current patterns of, for genetic tests, 163–66; economic theory of optimal, 159–60; heterogeneity of, 161–67; from homogeneity to heterogeneity of, 169–73; optimal, and shape of distribution of marginal benefits, 161; optimal pattern of, 159–60; simple theories of, 167–69; of testing, 160
- intellectual property rights, 308

- intensity-modulated radiation therapy (IMRT), 5, 222; impact of, with breast cancer case, 218–19; physician treatment settings and, 222–24; regression-adjusted differences in receipt of, 226–30; trends in treatment patterns, 224–25
- Investigational New Drug (IND), 311
- investors: orphan drug development and, 306; orphan drug designations and, 306–7
- IPOs. *See* initial public offerings (IPOs)
- LA (linkage analysis), 25
- likely precision medicines (LPMS), 118, 122–23; biomarker types in trials of, 138, 139–40f; in cancer trials, 138, 142f; characterizing development pipeline for, 133–38; in clinical trials, 135–38, 141f, 143; clinical trials for, 136f; clinical trials for, cancer indications only, 141f, 142t; clinical trials for, US trials only, 143f; defined, 132–33, 133; development pipeline of, characterizing, 133–54; development pipeline of, institutional factors for, 138–54; linkage analysis studies of, 25; predicting trials for, 149–54, 150t, 151t; publicly listed firms involved in trials of (1995–2016), 147t, 148t; regression analyses for, 149–54, 150–51t; trials for (1995–2016), 137t; types of biomarkers used in trials for, 138, 139–40f; types of firms engaged in development of, 144–53, 145–46f. *See also* precision medicine
- LPMS. *See* likely precision medicines (LPMS)
- multiple sclerosis, 187–88; case study in, 198–208
- MyCode Community Health Initiative, 275–76
- National Health Insurance (NHI) program of Taiwan, 242–43; breast cancer and its treatment in, 243–45; conceptual framework for individuals with breast cancer, 246–48; data description for study, 248–51; empirical methodology, 251–53; results of study of breast cancer patients, 253–68. *See also* personalized and precision medicine (PPM); personalized medicine
- National Institutes of Health (NIH), drug-development pipeline for, 4
- NDA (New Drug Application) approval, 310–11
- net monetary benefit (NMB), 60–62
- network medicine, 23
- New Drug Application (NDA) approval, 310–11
- new therapies, 26f; data for, 25–27
- next-generation sequencing (NGS): method, 25; studies, 25
- NHI. *See* National Health Insurance (NHI) program of Taiwan
- NIH (National Institutes of Health), drug-development pipeline for, 4
- ODA (Orphan Drug Act) of 1983, 308
- ODDs. *See* orphan drug designations (ODDs)
- oligopolies, precision medicine and, 89
- one- and two-way sensitivity analysis, 75–77, 76, 77t
- optimal insurance: general theory of, 161; issues in, when markets are not competitive, 162–63; issues in design of, 162–63; optimal proposition for, 162; and pricing, 162–63
- Orphan Drug Act of 1983 (ODA), 308
- orphan drug designations (ODDs): advantages of, 310; alternative models, 326–28, 327t; certification and reputational value of, 310; control variables, 315–17; cost of, 309–11; data sources for study of, 311–12; discussion of results, 328–31; firm performance and, 311; hypothesis for, as valuable intangible assets and market signals, 309–10; investors and, 306–7; as market signals, 311; measures for, 314–15; model for testing hypothesis, 319–22; power of certification of, 310; reputational value of, 310; results, 322–26; robustness checks, 326–28; sample application description, 312–14; summary statistics, 317–19, 318t; as valuable intangible assets, 310–11
- orphan drugs: firm performance and, 311; initial public offerings (IPOs) and, 305–6; investors and development of, 306; as tangible assets, 305–6
- orphan drugs legislation, 6, 305–6; review of rare disease drug development market and, 307–8

- orphan drugs sponsors, 311; sources of funding for, 308
- patent life, for drugs, 118n6
- patient heterogeneity, 186
- personalized and precision medicine (PPM): care delivery and, 1; as continuation of broader trend in medicine, 3; costs of, and health disparities, 5–6; coverage for, 4–5; defined, 1; drug-development pipeline for, 4; effects of, on industry, 1–2; efficacy of, 5; factors influencing growth in, 2; game theory and, 4; R&D and, 4; universal features of economic/clinical factors affecting, 237–41; value of, 2. *See also* National Health Insurance (NHI) program of Taiwan; Taiwan
- personalized medicine: cost considerations for innovations in, 208–9; coverage of, in Asia, 241–42; economic value of, 10; learning about treatment value and, 14; optimal pricing of, 16–18; physicians and, 217–19; potential health impacts of, 187, 194–98; practice setting and, 230–32; pricing of combination product of, 16–18; risk assessment and, 191–92; as technological change, 13–14; treatment-specific diagnostics and, 9–10; understanding value of, 187–88; value of, 14–15, 15f. *See also* National Health Insurance (NHI) program of Taiwan; Taiwan
- PGx. *See* pharmacogenomics (PGx)
- pharmaceutical innovations, types of, 188–92
- pharmaceutical treatments, 185–86; measuring health impact of, 192–98
- pharmacogenomic model: generic, 62–64; limitations, 78–80; mapping CPIC Level-A drugs to, 64–65, 66t
- Pharmacogenomic Resource for Enhanced Decisions In Care and Treatment (PREDICT) program, 59–60
- pharmacogenomic testing strategies, 56–60, 57f; multiplexed, 57; reimbursement policy for, 57–58; serial testing of single genes, 56–57
- pharmacogenomics (PGx), 3–4, 273; defined, 53–54; evidence for implementations of, 59–60; existing research on value of, 54; finding better evidence for, 58–59; overvalue of, 54–55; promise of, 54; using data for outcomes research, 6
- physicians, choice of treatments and, 217–19
- PML. *See* progressive multifocal leukoencephalopathy (PML)
- PPM. *See* personalized and precision medicine (PPM)
- practice setting, personalized medicine and, 230–32
- precision medicine Bertrand competition, 104–6; defending against, 106
- precision medicine game: emerging multiclass, 108; phased, 108–10
- Precision Medicine Initiative (2015), 186
- precision medicine prisoners' dilemma, variations of: dosing game, 101–2; stopping game, 102–3
- precision medicine, 87–89; biomarkers and, 119–21; data used for study of, 127–33; decision processes for determining which drugs to bring to market and, 117; defined, 115, 116; drug development process and, 119–23; economic incentives for, 116–18; economics of, 123–27; emerging multiclass, 107–8; features of, and game theory, 90–93; heterogeneity in treatment effects across patients and, 186; implications of *CYP2C19* study for, 300–301; interior cost sharing of tests in, 161; investments in, 115–16; oligopolies and, 89; potential impact of, 186–87. *See also* likely precision medicines (LPMs)
- predictability, imperfect test, 173–74
- PREDICT (Pharmacogenomic Resource for Enhanced Decisions in Care and Treatment) program, 59–60
- Prescription Drug Use Fee Act of 1992, 311
- progressive multifocal leukoencephalopathy (PML), as side effect, 191, 199, 206–8
- prisoners' dilemma. *See* diagnostic cutoff prisoners' dilemma; precision medicine prisoners' dilemma
- probabilistic sensitivity analysis (PSA), 55, 65–71
- quality-adjusted life years (QALYs), 186, 186n2
- R&D actors, role of major pharmaceutical as, 122–23
- risk assessment: impact of individual treat-

- ment effect on, 197–98; personalized medicine and, 191–92
- SEER-Medicare data, 224
- serial testing of single genes strategy, 56–57
- simple pharmacogenomic model structure, 62–64; limitations of, 78–80; mapping CPIC Level-A drugs to, 64–65
- start-ups, biotech, 308
- stopping game, 102–3
- Taiwan, 243–45; experiences of personalized and precision medicine in, 6; health system of (*see* National Health Insurance [NHI] program of Taiwan). *See also* breast cancer treatment, Taiwanese study of; personalized and precision medicine (PPM); personalized medicine
- targeted interventions, concept of, 115
- test predictability, imperfect, 173–74
- therapies, new, 26f; data for, 25–27
- Thomson Reuters Cortellis. *See* Cortellis
- treatment choice: clinical background for, 221–22; data for, 224; model of, 219–21; physicians settings and, 222–24; review of model of, 219–21; trends in, 224–25
- treatments, 13; error choices in, 10; individual-specific, 10, 11; patient's prior beliefs about, 11–12; population-wide, 10, 11
- treatment-specific diagnostics, personalized medicine and, 9–10
- treatment value: learning about individual, through experience, 11–16; testing for, 10–11
- Type I and II errors in treatments, 10, 13
- value of information (VOI) analysis, 55, 60–62; results, 71–78
- Vanderbilt University Medical Center (VUMC), 59–60
- variant-disease association (VDA), data for, 27–29